Feng Yanru, Pan Xintong, Li Ziqian, Li Yue, Sun Ya'nan, Yang Shaokun, He Chaoxing, Dang Yunjie, Huang Lu, Xiang Bai
Department of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Hebei Key Laboratory of Innovative Drug Research and Evaluation, Hebei Medical University, Shijiazhuang 050017, China.
Pharmaceutics. 2025 Jan 1;17(1):45. doi: 10.3390/pharmaceutics17010045.
Rheumatoid arthritis (RA) is a debilitating autoimmune disorder characterized by chronic inflammation and joint damage. Despite advancements in treatment, complete remission remains elusive. In this study, we introduce a novel lipid nanoparticle formulation co-delivering hydroxychloroquine (HCQ) and siRNA targeting TNF-α (si) using microfluidic technology, marking the first use of such a combination for RA therapy. In LPS-stimulated RAW 264.7 cells, the nanoparticles effectively reduced inflammatory markers. When administered via an intra-articular injection in a rat model, they significantly decreased joint inflammation and demonstrated good biological safety. This pioneering approach highlights the potential of lipid nanoparticles as a dual-delivery platform for enhanced RA treatment through targeted intra-articular administration.
类风湿性关节炎（RA）是一种使人衰弱的自身免疫性疾病，其特征为慢性炎症和关节损伤。尽管治疗取得了进展，但完全缓解仍难以实现。在本研究中，我们使用微流控技术引入了一种新型脂质纳米颗粒制剂，该制剂可共同递送羟氯喹（HCQ）和靶向TNF-α的小干扰RNA（si），这是首次将这种组合用于RA治疗。在脂多糖刺激的RAW 264.7细胞中，纳米颗粒有效降低了炎症标志物。当通过关节内注射给药于大鼠模型时，它们显著减轻了关节炎症并显示出良好的生物安全性。这种开创性方法突出了脂质纳米颗粒作为双重递送平台，通过靶向关节内给药增强RA治疗的潜力。
